Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2022-08-08 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于公司涉及诉讼的进展公告
Legal Proceedings Report Classification · 100% confidence The document is a public announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of litigation involving the company. It details court decisions, references previous announcements about lawsuits, and discusses the impact of the litigation on company profits. The document does not contain financial statements or detailed financial analysis but focuses on legal proceedings and updates on lawsuits. It is not a full annual or interim report, nor an earnings release or management discussion. The content fits the category of Legal Proceedings Report, which covers updates on significant lawsuits and regulatory legal matters involving the company.
2022-08-08 Chinese
金陵药业股份有限公司2021年年度分红派息实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2021 annual dividend distribution by Jinling Pharmaceutical Co., Ltd. It details the dividend amount, record dates, payment dates, and related shareholder information. It references the approval of the profit distribution plan at the 2021 annual general meeting and provides specifics on dividend payment procedures. The document is short (1649 characters) and serves as a formal notice of dividend payment rather than a full financial report or annual report. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-08-03 Chinese
金陵药业股份有限公司关于收到部分拆迁补偿款的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the receipt of partial demolition compensation funds. It details the amounts received, references previous announcements, and discusses the accounting treatment and impact on the company's performance. The document is short (899 characters) and serves as a notification of a specific financial event rather than a comprehensive financial report or detailed management discussion. It does not contain full financial statements or detailed analysis, nor is it a regulatory certification or voting result. Therefore, it fits best under the category of a Regulatory Filing (RNS), which is a fallback for miscellaneous announcements that do not fit other specific categories.
2022-07-19 Chinese
金陵药业股份有限公司关于调整公司高级管理人员职务及聘任公司总裁助理的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding changes in senior management positions, specifically the adjustment of a senior executive's role and the appointment of a new assistant to the president. It includes details about the board meeting approving these changes and mentions the stock holdings of the outgoing executive. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming the classification.
2022-07-08 Chinese
金陵药业股份有限公司独立董事关于聘任公司高级管理人员的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the appointment of senior management personnel at Jinling Pharmaceutical Co., Ltd. It references compliance with company bylaws and regulatory rules, and confirms qualifications and absence of disqualifying conditions for the appointees. The content focuses on management changes and approvals rather than financial data or report publication. The document length is short (691 characters) and it is not a report or announcement of a report publication. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2022-07-08 Chinese
金陵药业股份有限公司第八届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions from the 21st meeting of the 8th Board of Directors of Jinling Pharmaceutical Co., Ltd. It details changes in board committees, appointments of senior management, and internal organizational adjustments. There are no financial statements or detailed financial data present. The content focuses on board and management changes, including appointments and resignations of executives. This fits the category of Board/Management Information (MANG). The document length is 2420 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2022-07-08 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.